Filter by country
Africa
Sao Tome and Principe
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Lesotho
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Cote d'Ivoire
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Angola
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
South-East Asia
Bangladesh
Bhutan
China
Korea, DPR
India
Indonesia
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by Category
Documents
Gavi Process Guidelines
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Russian
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
White papers
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
Annual Reports
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Board
Committee
Members

Documents (9878)

Showing 12 of 9878 View All
Showing 137 of 824 pages

Gavi Alliance Market Shaping Strategy 2021-2025

Gavi's fourth strategic goal is to ensure sustainable, healthy market dynamics for vaccines and immunisation-related products; to incentivise innovation for the development of suitable vaccines; and to scale-up innovative immunisation-related products.

Annual Audit and Investigations report: Gavi Board meeting, June 2021

1



Board -2021 -Mtg -2-Doc C


Section A: Executive Summary
Context
The Managing Director of the Audit and Investigations (A&I) function is required to
report to the Board at least annually. Given the constraints on time for th e June
2021 meeting, it has been agreed to postpone that report until the December 2021
meeting.
This report should be considered as an interim u pdate therefore on the status of
A&I?s activity given the current context for Gavi 5.0 and COVAX , and the
challenges th ese present for the conduct of the audit activity in Gavi . A final report
on A&I?s 2021 activity, including a fuller assessment of the work around the
COVAX Facility, will be provided to the Board at its December 2021 meeting.
There are no matters of significance to bring to the Board?s attention at this time .
A&I reports routinely on its work activity to the Audit and Finance Committee ( AFC )
at each of its meetings.
Recognising that certain Board members are not familiar with A&I , Annex A
provides a short overview of the function?s background and activities.
Questions this paper addresses
What is the impact on A&I ?s ability to conduct audits and other reviews of: (a) the
Secretariat working remotely from the office ; and (b) the inability to travel to
perform audits of programmes or investigations in country ?
How is A&I responding to the challenges of assessing management?s identification
of risk s related to COVAX and COVID -19 vaccine delivery, and their m itigation ?
Conclusions
As previously reported to the Board , the need to work remotely had some impact
on the conduct of A&I? s work within the Secretariat . More significantly, because of
the inability to travel to eligible countries , in early 2020 A&I suspe nd ed its
programme audit activity and certain follow -up work of an investigatory nature . In
2021 pr ogramme audits are resuming through the use of consultants in country
with A&I staff engaging in the audits remotely until travel can recommence ; any
other follow -up work will be undertaken directly by A&I when travel resumes .
SUBJECT : REPORT OF AUDIT AND INVESTIGATIONS
Agenda item: C
Category: For Information
Report to the Board
23 -24 June 2021

Subscribe to our newsletter